Interleukin 10 (IL-10) Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Interleukin 10 (IL-10) is an anti-inflammatory cytokine that plays a vital role in maintaining the balance of immune responses, allowing the clearance of infection while minimizing damage to the host.  It is synthesized by various types of cells in the body, like NK cells, B-cells, and T-cells. It is a pro-inflammatory cytokine that plays a significant role in inhibiting cytokine production and Th1 and Th2 cell activation. Any infection or inflammatory condition that signals an infection in the body against which the level of IL-10 scaled causes an increase in IL-10 levels. Therefore, IL-10  is associated with many diseases like vascular diseases, Rheumatoid Arthritis, Acute Myelogenous Leukemia, Blood Platelet disorders, various kinds of lymphomas like Follicular lymphoma, and others. It has also been linked with many neurodegenerative diseases wherein it played a role in preventing inflammation-mediated neuronal degradation. Hence, it acts to avoid inflammation in disorders such as Multiple Sclerosis, Alzheimer’s disease, Parkinson’s disease, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (AML), and others. Research is being conducted globally to discover new and novel molecules to be used as H1 Histamine antagonists. The development and launch of new products will thus increase the revenue of the market in the forecasted years. According to the Parkinson’s Foundation, more than 10 million people are living with Parkinson’s disease globally, while 90,000 people are diagnosed with it each year in the USA alone. It is projected that 1.2 million people in the USA will live with Parkinson’s by 2030. Therefore, there is ample opportunity for the market players globally.

A number of these inhibitors are in the market, while many are in ongoing clinical trials. Various companies have various products in their pipelines, with 49 products in different stages of clinical trials, with 2 in Phase 3, 16 in Phase 2, and 7 in Phase 1 of the clinical trials.

Drugs in the Pipeline of IL-10

• Eyevinal (Ibudilast)
• Orismilast Oral (LEO 32731)
• Pegilodecakin (LY3500518)
• Dekavil (F8-IL10)
• XT-150
• AMT-101
• Galepa (Daleuton Topical)
• Thykamine (PUR 0110)
• HMPL-011
• Tenovil (Ilodecakin)
• Beta Alethine (Ax-101)
• ATX-MS-1467
• BT-063
• DTRM-555
• KLS-2031
• Prevascar (Ilodecakin)
• AG011
• AG019
• APVO210
• DK210
• IAE0972
• XT-150 Intrathecal
• Faecalibacterium Prausnitzii EXL01-Strain (EXL01)
• Lenalidomide Subcutaneous Prolonged-Release (NEX-20A)
• Orismilast Topical (LEO 32731 Topical)

Clinical Activity and Developments of Interleukin 10 (IL-10)

As of June 2023, various companies have approximately 49 products for 581 diseases. For these diseases, many trials are being conducted by players globally. For instance,

• Cambridge University Hospitals NHS Foundation Trust is conducting a Phase 3 clinical trial to study the efficacy of ibudilast as an adjuvant treatment to Decompressive surgery for Degenerative Cervical myopathy that is expected to complete by September 2026.
• Union Therapeutics is conducting a Phase 2 clinical trial study on the efficacy and safety of Orismilast in adults with Atopic Dermatitis (AD) that is expected to complete by July 2023.